dacarbazine

biocarbazine R dacarbazinum 4(5)-(3,3- dimethyl-1-triazeno)imidazole-4-carboxamide 5-(3,3- dimethyl-1-triazeno)imidazole-4-carboxamide 4-(3,3- dimethyl-1-triazeno)imidazole-5-carboxamide 4-(5)-(3,3- dimethyl-1-triazeno)imidazole-5(4)-carboxamide 4-(or 5)-(3,3- dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide (5E)-5-( dimethylaminohydrazinylidene)imidazole-4-carboxamide 5-( dimethyltriazeno)imidazole-4-carboxamide 5-(3,3- dimethyltriazeno)imidazole-4-carboxamide dimethyltriazeno)imidazolecarboxamide imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazeno)- imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazenyl)- 1H- imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazenyl)- PubMed: Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy. PubMed: Immunotherapy in Melanoma: Recent Advances and Promising New Therapies. PubMed: Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway. PubMed: Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. PubMed: Brentuximab vedotin: first-line agent for advanced Hodgkin lymphoma. PubMed: Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma. PubMed: Treatment with ipilimumab: a case report of complete response in a metastatic malignant melanoma patient. PubMed: [Vemurafenib (Zelboraf) in the therapy of melanoma]. PubMed: Lycopene modulates growth and survival associated genes in prostate cancer. PubMed: The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. PubMed: [Antibody therapies for melanoma]. PubMed: Metastatic melanoma - a review of current and future drugs. PubMed: New therapeutical strategies in the treatment of metastatic disease. PubMed: Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. PubMed: Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system. PubMed: Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma. PubMed: Upcoming strategies for the treatment of metastatic melanoma. PubMed: Combination of oncolytic adenovirus and dacarbazine attenuates antitumor ability against uveal melanoma cells via cell cycle block. PubMed: Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma. PubMed: Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma. PubMed: New drugs in melanoma: it's a whole new world. PubMed: Hematologic adverse events associated with temozolomide. PubMed: FDA accelerated approval benefits glioblastoma. PubMed: Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. PubMed: On assessing the presence of evaluation-time bias in progression-free survival in randomized trials. PubMed: Malignant melanoma (metastatic). PubMed: Combination of dacarbazine and dimethylfumarate efficiently reduces melanoma lymph node metastasis. PubMed: Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. PubMed: Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy. PubMed: Neurological adverse effects caused by cytotoxic and targeted therapies. PubMed: Adjuvant fermented wheat germ extract (Avemar) nutraceutical improves survival of high-risk skin melanoma patients: a randomized, pilot, phase II clinical study with a 7-year follow-up. PubMed: Malignant melanoma (metastatic). PubMed: Melanoma: immunotherapeutic approaches. PubMed: Genasense: it ain't over till the fat lady sings. PubMed: Cutaneous melanoma: available therapy for metastatic disease. PubMed: Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. PubMed: Update on the systemic treatment of malignant melanoma. PubMed: Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. PubMed: Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. PubMed: A survey of treatments used in patients with metastatic melanoma: analysis of 189 patients referred to the National Cancer Institute. PubMed: Intraindividual variations of DNA adduct levels in humans. PubMed: Dose comparison of tropisetron (Navoban) 5 mg and 10 mg orally in the prophylaxis of dacarbazine-induced nausea and emesis.